The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review

References

• Viera AJ, Wouk N. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician. 2015;92:487–495.
   PubMed Web of Science ®Google Scholar
• Soar J, Perkins G, Abbas G, al. e. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation. 2010;81:1400–1433.
   PubMed Web of Science ®Google Scholar
• Tran HA. Extreme hyperkalemia. South Med J. 2005;98:729–732.
   PubMed Web of Science ®Google Scholar
• Lehnhardt A, Kemper M. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26:377–384.
   PubMed Web of Science ®Google Scholar
• Spodick DH. Effects of severe hyperkalemia. Am Heart Hosp J. 2008;6:68.
   PubMedGoogle Scholar
• Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109:1510–1513.
   PubMed Web of Science ®Google Scholar
• Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156–1162.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. CJASN. 2012;7:1234–1241.
   PubMed Web of Science ®Google Scholar
• Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial. 2001;14:348–356.
   PubMed Web of Science ®Google Scholar
• Foley RN, Gilbertson DT, Murray T, et al. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med. 2011;365:1099–1107.
   PubMed Web of Science ®Google Scholar
• Fotheringham J, Fogarty DG, El Nahas M, et al. The mortality and hospitalization rates associated with the long interdialytic gap in thrice-weekly hemodialysis patients. Kidney Int. 2015;88:569–575.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. w64.
   PubMed Web of Science ®Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–384.
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Methods guide for effectiveness and comparative effectiveness reviews. Rockville (MD): AHRQ Methods for Effective Health Care; 2008.
   Google Scholar
• The R Foundation. The R Project for Statistical Computing 2018 [updated 2018 Sep 14]. Available from: https://www.r-project.org/
   Google Scholar
• Ahmad Z. Hyperkalemia as a medical emergency in patients with ESRD in hemodialysis. Pak J Med Sci. 2010;26:117–122.
   Web of Science ®Google Scholar
• Balamuthusamy S, Reddi A, et.al. Prevalence of hyperkalaemia in patients with ESRD undergoing haemodialysis. J Am Soc Nephrol. 2017;28:388.
   Google Scholar
• Belmar Vega L, Galabia ER, Bada da Silva J, et al. Epidemiology of hyperkalemia in chronic kidney disease. Nefrologia: Publicacion oficial de la Sociedad Espanola Nefrologia; 2019.
   Google Scholar
• Block GA, Chertow GM, Sullivan JT, et al. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS One. 2019;14:e0213774.
   PubMed Web of Science ®Google Scholar
• Block GA, Rosenbaum DP, Leonsson-Zachrisson M, et al. Effect of tenapanor on interdialytic weight gain in patients on hemodialysis. CJASN. 2016;11:1597–1605.
   PubMed Web of Science ®Google Scholar
• Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int. 2011;80:978–985.
   PubMed Web of Science ®Google Scholar
• Charytan D, Himmelfarb J, et.al. Safety and cardiovascular efficacy of spironolactone (SPL) in dialysis-dependent ESRD (Spin-D): S pilot trial of the NIDDK haemodialysis novel therapies consortium. J Am Soc Nephrol. 2017;28:B9.
   Google Scholar
• Charytan DM, Himmelfarb J, Ikizler TA, et al., Hemodialysis Novel Therapies Consortium. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 2019;95:973–982.
   PubMed Web of Science ®Google Scholar
• Checherita IA, David C, Diaconu V, et al. Potassium level changes–arrhythmia contributing factor in chronic kidney disease patients. Romanian J Morphol Embryol. 2011;52:1047–1050.
   PubMed Web of Science ®Google Scholar
• Cho JH, Hwang JY, Lee SE, et al. Nutritional status and the role of diabetes mellitus in hemodialysis patients. Nutr Res Pract. 2008;2:301–307.
   PubMedGoogle Scholar
• Cobo Sanchez JL, Alconero Camarero AR, Casaus Perez M, et al. Hyperkalaemia and haemodialysis patients: eletrocardiographic changes. J Ren Care. 2007;33:124–129.
   PubMedGoogle Scholar
• de Almeida L, Sette L, Fonseca F, et al. Metabolic and volume status evaluation of hemodialysis patients with and without residual renal function in the long interdialytic interval. J Bras Nefrol. 2019;41:481–491.
   PubMedGoogle Scholar
• Douvris A, Zeid K, Hiremath S, et al. Safety lapses prior to initiation of hemodialysis for acute kidney injury in hospitalized patients: a patient safety initiative. JCM. 2018;7:317.
   Google Scholar
• Khedr E, Abdelwhab S, El-Sharkawy M, et al. Prevalence of hyperkalemia among hemodialysis patients in Egypt. Ren Fail. 2009;31:891–898.
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr, Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. The Lancet HIV. 2019;6:e15–e24.
   Web of Science ®Google Scholar
• Farese S, Kruse A, Pasch A, et al. Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients. Kidney Int. 2009;76:877–884.
   PubMed Web of Science ®Google Scholar
• Frazão CM, de Sá JD, Medeiros AB, et al. The adaptation problems of patients undergoing hemodialysis: socio-economic and clinical aspects. Rev Lat Am Enfermagem. 2014;22:966–972.
   PubMed Web of Science ®Google Scholar
• Garagarza CA, Valente AT, Oliveira TS, et al. Effect of personalized nutritional counseling in maintenance hemodialysis patients. Hemodial Int. 2015;19:412–418.
   PubMed Web of Science ®Google Scholar
• Genovesi S, Valsecchi MG, Rossi E, et al. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant. 2009;24:2529–2536.
   PubMed Web of Science ®Google Scholar
• Hammer F, Malzahn U, Donhauser J, et al., MiREnDa Study Group. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int. 2019;95:983–991.
   PubMed Web of Science ®Google Scholar
• Han SW, Won YW, Yi JH, et al. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007;22:1150–1155.
   PubMed Web of Science ®Google Scholar
• He YL, Yang SJ, Hu CH, et al. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol Ther. 2018;47:526–532.
   PubMed Web of Science ®Google Scholar
• Hooker R, Young M, Hendey GW. Hyperkalemia frequently presents as symptomatic bradycardia in the prehospital setting. Acad Emerg Med. 2015;22:S86.
   Google Scholar
• Huang CW, Lee MJ, Lee PT, et al. Low potassium dialysate as a protective factor of sudden cardiac death in Hemodialysis patients with Hyperkalemia. PLoS One. 2015;10:e0139886.
   PubMed Web of Science ®Google Scholar
• Hussain S, Dreyfus DE, Marcus RJ, et al. Is spironolactone safe for dialysis patients? Nephrol Dialy Transplant. 2003;18:2364–2368.
   PubMed Web of Science ®Google Scholar
• Hwang JC, Wang CT, Chen CA, et al. Hypokalemia is associated with increased mortality rate in chronic hemodialysis patients. Blood Purif. 2011;32:254–261.
   PubMed Web of Science ®Google Scholar
• Iseki K, Arima H, Kohagura K, et al., Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant. 2013;28:1579–1589.
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Xu H, Morgenstern H, et al. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney Int. 2018;94:589–598.
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Zee J, Brunelli SM, et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2017;69:266–277.
   PubMed Web of Science ®Google Scholar
• Kim T, Rhee CM, Streja E, et al. Racial and ethnic differences in mortality associated with serum potassium in a large hemodialysis cohort. Am J Nephrol. 2017;45:509–521.
   PubMed Web of Science ®Google Scholar
• Knoll GA, Sahgal A, Nair RC, et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112:110–114.
   PubMed Web of Science ®Google Scholar
• Kourtellidou S, Ashby D, et.al. Oral sodium bicarbonate reduces inter-dialytic potassium gain – the BicHD trial. J Am Soc Nephrol. 2016;27:595A.
   PubMedGoogle Scholar
• Kovesdy CP, Regidor DL, Mehrotra R, et.al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. CJASN. 2007;2:999–1007.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Rowan CG, Conrad A, et al. Real-World evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int Rep. 2019;4:301–309.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Kim S, Park I, et al. Comparison of estimated glomerular filtration rate equations at the time of hemodialysis initiation. Kidney Res Clin Pract. 2015;34:207–211.
   PubMed Web of Science ®Google Scholar
• Lin HH, Yang YF, Chang JK, et al. Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients. Ren Fail. 2009;31:942–945.
   PubMed Web of Science ®Google Scholar
• Maoujoud O, Zajjari Y, Asseraji M, et al. Commentary: the practice of dialysis in the intensive care unit in a developing country. Ethnicity Disease. 2014;24:226–228.
   PubMed Web of Science ®Google Scholar
• Mattos A, Sanches L, Bibian M, et al. Clinical characteristics of patients treated by hemodialysis. Kidney Res Clin Pract. 2012;31:A57– A7.
   Google Scholar
• Movilli E, Camerini C, Gaggia P, et al. Use of renin-angiotensin system blockers increases serum potassium in anuric hemodialysis patients. Am J Nephrol. 2018;48:79–86.
   PubMed Web of Science ®Google Scholar
• Nemati E, Taheri S. Electrocardiographic manifestations of hyperkalemia in hemodialysis patients. Saudi J Kidney Dis Transplant. 2010;21:471–477.
   PubMedGoogle Scholar
• Patil VC, Kulkarni C, Rajput A, et al. Incidence, etiology and clinical profile of newly detected Chronic kidney disease (CKD) at teaching hospital. Res J Pharmaceut Biol Chem Sci. 2015;6:1092–1110.
   Google Scholar
• Poulikakos D, Shah A, Persson M, et al. Safety and efficacy of beta blockers in haemodialysis. Nephrol Dial Transplant. 2012;27:ii248.
   Web of Science ®Google Scholar
• Pourfarziani V, Ghanbarpour F, Nemati E, et al. Laboratory variables and treatment adequacy in hemodialysis patients in Iran. Saudi J Kidney Dis Transplant. 2008;19:842–846.
   PubMedGoogle Scholar
• Raza H, Courts A, Quadri K, et al. The effect of active nutritional counseling in improving biochemical nutritional parameters and fluid overload problems in maintenance hemodialysis patients. Saudi J Kidney Dis Transplant. 2004;15:140–143.
   PubMedGoogle Scholar
• Robertson J, Benner D, Levine R. Analysis of potassium profiles among hemodialysis (HD) patients. Am J Kidney Dis. 2009;53:A65.
   Web of Science ®Google Scholar
• Ross J, DeatherageHand D. Evaluation of potassium levels before hemodialysis access procedures. Semin Dial. 2015;28:90–93.
   PubMed Web of Science ®Google Scholar
• Sacchetti A, Stuccio N, Panebianco P, et al. ED hemodialysis for treatment of renal failure emergencies. Am J Emerg Med. 1999;17:305–307.
   PubMed Web of Science ®Google Scholar
• Singh B, Block G, Lerma EV, et al. Hyperkalemia and serum potassium variability in patients on hemodialysis. Am J Kidney Dis. 2017;69:A3.
   PubMedGoogle Scholar
• Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transplant. 2009;20:392–397.
   PubMedGoogle Scholar
• Tzamaloukas AH, Avasthi PS. Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis. Am J Nephrol. 1987;7:101–109.
   PubMed Web of Science ®Google Scholar
• Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1380–1387.
   PubMed Web of Science ®Google Scholar
• Walsh M, Manns B, Garg AX, et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol. 2015;10:1602–1608.
   PubMed Web of Science ®Google Scholar
• Yalin SF, Trabulus S, Yalin AS, et al. Factors associated with mortality in patients underwent emergency hemodialysis. Nephrol Dial Transplant. 2012;27:ii211–ii2.
   Web of Science ®Google Scholar
• Yang G, Wang J, Sun J, et al. Perioperative hyperkalemia in hemodialysis patients undergoing parathyroidectomy for renal hyperparathyroidism. Intern Emerg Med. 2019;14:1065–1071.
   PubMed Web of Science ®Google Scholar
• Yusuf AA, Hu Y, Singh B, et al. Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study. Am J Nephrol. 2016;44:179–186.
   PubMed Web of Science ®Google Scholar
• Acha K, Awasume E, Ama Moor V, et al. SAT-216 factors associated with disorders of serum potassium in patients on maintenance hemodialysis in a facility without a renal dietician. Kidney Int Rep. 2020;5:S92–S3.
   Google Scholar
• Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12-weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71:660–665.
   PubMed Web of Science ®Google Scholar
• Brown P, Omar RL. S. The indications and timing of haemodialysis in critically ill patients with acute kidney injury admitted to ICU. Southern Afr J Crit Care. 2019;35:34–35.
   Google Scholar
• Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381:1011–1022.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Ford M, Fukagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. JASN. 2019;30:1723–1733.
   Web of Science ®Google Scholar
• Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382:222–232.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Spinowitz BS, Wisemandle WA, et al. Randomized controlled trial of subcutaneous epoetin alfa-epbx versus epoetin alfa in end-stage kidney disease. Kidney Int Rep. 2019;4:1235–1247.
   PubMed Web of Science ®Google Scholar
• Jebali H, Ghabi H, Mami I, et al. Evaluation of electrocardiographic findings before and after hemodialysis session. Saudi J Kidney Dis Transplant. 2020;31:639–646.
   PubMed Web of Science ®Google Scholar
• Megahed AF, Tawfik M, Holes G, et al. Enoxaparin use as an anticoagulant during hemodialysis is associated with therapeutic benefits. Nephrol Dial Transplant. 2019;34:a514.
   Web of Science ®Google Scholar
• Nyandwi J, Ndirahisha E, Manirakiza S, et al. SUN-006 prognosis of acute kidney injury in the era of renal replacement therapy in Burundi. Kidney Int Rep. 2020;5:S206–S207.
   Google Scholar
• Rafique Z, Aceves J, Espina I, et al. Can physicians detect hyperkalemia based on the electrocardiogram? Am J Emerg Med. 2020;38:105–108.
   PubMed Web of Science ®Google Scholar
• Thomas A, Silver SA, Perl J, et al. The frequency of routine blood sampling and patient outcomes among maintenance hemodialysis recipients. Am J Kidney Dis. 2020;75:471–479.
   PubMed Web of Science ®Google Scholar
• Triqui C, Najjar M, Ben Amor S, et al. SAT-094 hemodialysis emergencies in a nephrology department: about 117 cases. Kidney Int Rep. 2020;5:S42.
   Google Scholar
• Vaz de Melo Ribeiro P, Miranda Hermsdorff HH, Balbino KP, et al. Effect of a nutritional intervention, based on transtheoretical model, on metabolic markers and food consumption of individuals undergoing hemodialysis. J Ren Nutr. 2020;30:430–439.
   PubMed Web of Science ®Google Scholar
• Woods J, Polkinghorne K, Kerr P, et al. SUN-321 investigating the effectiveness and safety of a very low calorie diet (VLCD) as a method of weight loss in patients receiving haemodialysis therapy. Kidney Int Rep. 2019;4:S293.
   PubMedGoogle Scholar
• Alagusundaramoorthy S, Gregory A, et.al. Timing is everything: decreasing mortality in severe hyperkalemia. J Am Soc Nephrol. 2018;29:500.
   Google Scholar
• Balle C, Schollmeyer P. Morbidity of patients with analgesic-associated nephropathy on regular dialysis treatment and after renal transplantation. Klin Wochenschr. 1990;68:38–42.
   PubMedGoogle Scholar
• Chaaban A, Abouchacra S, Gebran N, et al. Potassium binders in hemodialysis patients: a friend or foe? Ren Fail. 2013;35:185–188.
   PubMed Web of Science ®Google Scholar
• Chatoth D, Wahl P, Rakov V, et al. FP531 Real-world outcomes of hyperkalemia management with patiromer in end-stage renal disease patients undergoing hemodialysis in the United States. Nephrol Dial Transplant. 2018;33:i218.
   Web of Science ®Google Scholar
• Ferrey A, You AS, Kovesdy CP, et.al. Dialysate potassium and mortality in a prospective hemodialysis cohort. Am J Nephrol. 2018;47:415–423.
   PubMed Web of Science ®Google Scholar
• Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. CJASN. 2012;7:765–774.
   PubMed Web of Science ®Google Scholar
• Li H, Wang SX. Analysis of death causes and its related factors in young patients on maintenance hemodialysis. Blood Purification. 2012;33:247–248.
   Google Scholar
• Lomonte C, Chiarulli G, Cazzato F, et al. End-stage renal disease in leprosy. J Nephrol. 2004;17:302–305.
   PubMed Web of Science ®Google Scholar
• Morduchowicz G, Winkler J, Derazne E, et al. Causes of death in patients with end-stage renal disease treated by dialysis in a center in Israel. Israel J Med Sci. 1992;28:776–779.
   PubMedGoogle Scholar
• Onuigbo M, Onuigbo N, Bellasi A, et al. Penultimate pulse wave velocity, better than baseline pulse wave velocity, predicted mortality in Italian ESRD cohort study – a case for daily hemodialysis for ESRD patients with accelerated pulse wave velocity changes. G Ital Nefrol. 2013;30:gin/30.2.22.
   PubMedGoogle Scholar
• Poulikakos D, Malik M, Banerjee D. Risk profiling based on cardiac autonomic modulation and repolarisation indices from intradialytic computerized electrocardiography. Nephrol Dial Transplant. 2015;30:iii560.
   Web of Science ®Google Scholar
• Pun PH, Herzog CA, Middleton JP. Improving ascertainment of sudden cardiac death in patients with end stage renal disease. CJASN. 2012;7:116–122.
   PubMed Web of Science ®Google Scholar
• Shibata M, Kishi T, Iwata H. Clinical study of complications in dialyzed diabetics. Tohoku J Exp Med. 1983;141 Suppl :417–425.
   PubMedGoogle Scholar
• Li M, Ye ZC, Li CM, et al. Low serum uric acid levels increase the risk of all-cause death and cardiovascular death in hemodialysis patients. Ren Fail. 2020;42:315–322.
   PubMed Web of Science ®Google Scholar
• Trajceska L, Selim G, Sikole A. Potassium level, malnutrition and mortality in dialysis patients. Int J Artif Organs. 2019;42:426.
   Google Scholar
• Zulham RM, Martini S, Widati S. Risk factor of early death in diabetic terminal renal failure patients receiving hemodialysis. Ind J Forensic Med Toxicol. 2019;13:1585–1590.
   Google Scholar
• Chatoth D, Wahl P, Rakov V, et al. Real-world outcomes of hyperkalemia management with patiromer in end-stage renal disease patients undergoing hemodialysis in the United States. Nephrol Dial Transplant. 2017;32:iii657.
   Web of Science ®Google Scholar
• Bleyer AJ, Hartman J, Brannon PC, et.al. Characteristics of sudden death in hemodialysis patients. Kidney Int. 2006;69:2268–2273.
   PubMed Web of Science ®Google Scholar
• Bleyer AJ, Russell GB, Satko SG, et.al. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999;55:1553–1559.
   PubMed Web of Science ®Google Scholar
• Fotheringham J, Sajjad A, Stel VS, et al. The association between longer haemodialysis treatment times and hospitalization and mortality after the two-day break in individuals receiving three times a week haemodialysis. Nephrol Dial Transplant. 2019;34:1577–1584.
   Google Scholar
• Fotheringham J, Smith M, Froissart M, et.al. The variation in hospitalisation and mortality following non-attendance for haemodialysis according to dialysis day of the week in a European cohort. Nephrol Dial Transplant. 2018;33:i344.
   Web of Science ®Google Scholar
• Karnik JA, Young BS, Lew NL, et.al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60:350–357.
   PubMed Web of Science ®Google Scholar
• Krishnasamy R, Badve SV, Hawley CM, et al. Daily variation in death in patients treated by long-term dialysis: comparison of in-center hemodialysis to peritoneal and home hemodialysis. Am J Kidney Dis. 2013;61:96–103.
   PubMed Web of Science ®Google Scholar
• Kumar P, Prabhu AR, Bairy M. Difference in interdialytic intervals leading to hospital admission and mortality in hemodialysis patients. Value Health. 2013;16:A636.
   Web of Science ®Google Scholar
• Lafrance JP, Nolin L, Senécal L, et al. Predictors and outcome of cardiopulmonary resuscitation (CPR) calls in a large haemodialysis unit over a seven-year period. Nephrol Dial Transplant. 2006;21:1006–1012.
   PubMed Web of Science ®Google Scholar
• Rhee C, You A, Streja E, et al. Dialysis schedule and day-of-week mortality in a national dialysis cohort. Nephrol Dial Transplant. 2017;32:iii355–iii357.
   Web of Science ®Google Scholar
• Roy-Chaudhury P, Tumlin JA, Koplan BA, et al., MiD investigators and committees. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93:941–951.
   PubMed Web of Science ®Google Scholar
• Tangweerapong K. Association between pre-dialysis electrolytes and incidence of arrhythmia in long inter-dialytic interval among chronic haemodialysis patients. J Am Soc Nephrol. 2017;1043.
   Google Scholar
• Tumlin J, Roy-Chaudhury P, Koplan B, et al., MiD investigators and Committees. Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study. BMC Nephrol. 2019;20:80.
   PubMed Web of Science ®Google Scholar
• Wong MCG, Kalman JM, Pedagogos E, et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm. 2015;12:2047–2055.
   PubMed Web of Science ®Google Scholar
• Zhang H, Schaubel D, Kalbfleisch J, al. e. Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-of-week mortality. Kidney Int. 2012;81:1108–1115.
   PubMed Web of Science ®Google Scholar
• Fotheringham J, Smith MT, Froissart M, et al. Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study. BMC Nephrol. 2020;21:218.
   PubMed Web of Science ®Google Scholar
• Chevarría J, Sánchez M, Pérez K, et al. Hyperkalemia in hemodialysis patients not all is said. NDT Plus. 2010;3:iii312.
   Google Scholar
• Kovesdy C. Management of hyperkalemia: an update for the internist. Am J Med. 2015;128:1281–1287.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP. Epidemiology of hyperkalemia: an update. Kidney Int Suppl (2011). 2016;6:3–6.
   PubMed Web of Science ®Google Scholar
• Palaka E, Grandy S, Darlington O, et al. Associations between serum potassium and adverse clinical outcomes: a systematic literature review. Int J Clin Pract. 2020;74:e13421.
   PubMed Web of Science ®Google Scholar
• Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34:iii2–iii11.
   PubMed Web of Science ®Google Scholar
• Rhee CM. Serum potassium and the long interdialytic interval: minding the gap. Am J Kidney Dis. 2017;70:4–7.
   PubMed Web of Science ®Google Scholar
• Brunelli SM, Du Mond C, Oestreicher N, et al. Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval. Am J Kidney Dis. 2017;70:21–29.
   PubMed Web of Science ®Google Scholar
• Marano M, Marano S, Gennari FJ. Beyond bicarbonate: complete acid-base assessment in patients receiving intermittent hemodialysis. Nephrol Dial Transplant. 2017;32:528–533.
   PubMed Web of Science ®Google Scholar